UK markets closed
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • FTSE 250

    22,948.83
    -101.63 (-0.44%)
     
  • AIM

    1,251.11
    +3.84 (+0.31%)
     
  • GBP/EUR

    1.1713
    -0.0024 (-0.20%)
     
  • GBP/USD

    1.3908
    -0.0050 (-0.35%)
     
  • BTC-GBP

    29,996.21
    -440.23 (-1.45%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • DOW

    34,935.47
    -149.06 (-0.42%)
     
  • CRUDE OIL

    73.81
    +0.19 (+0.26%)
     
  • GOLD FUTURES

    1,812.50
    -18.70 (-1.02%)
     
  • NIKKEI 225

    27,283.59
    -498.83 (-1.80%)
     
  • HANG SENG

    25,961.03
    -354.29 (-1.35%)
     
  • DAX

    15,544.39
    -96.08 (-0.61%)
     
  • CAC 40

    6,612.76
    -21.01 (-0.32%)
     

Fresenius Medical (FMS) Gains 1.1% Since Q1 Earnings Beat

·4-min read

Shares of Fresenius Medical Care AG & Co. KGaA FMS have gained 1.1% on May 11, following the company's first-quarter 2021 results.

The company reported first-quarter 2021 adjusted earnings per share (EPS) of 51 cents, which beat the Zacks Consensus Estimate of 45 cents by 13.3%. However, the bottom line declined 1.9% year over year.

Revenue Details

Revenues improved 2.5% year over year to $5.08 billion. However, the top line missed the Zacks Consensus Estimate by 4.1%.

Segmental Details

In the first quarter, Fresenius Medical reported through two segments — Health Care Services and Health Care Products.

Health Care Services revenues fell 7% on a year-over-year basis but grew 1% at constant currency (cc). The downside stemmed from a negative exchange rate impact, absence of a prior-year partial reversal of a revenue recognition adjustment along with COVID-19 effect and lower reimbursement for calcimimetics.

Fresenius Medical Care AG & Co. KGaA Price, Consensus and EPS Surprise

Fresenius Medical Care AG & Co. KGaA Price, Consensus and EPS Surprise
Fresenius Medical Care AG & Co. KGaA Price, Consensus and EPS Surprise

Fresenius Medical Care AG & Co. KGaA price-consensus-eps-surprise-chart | Fresenius Medical Care AG & Co. KGaA Quote

Health Care Products revenues dipped 1% year over year, while increasing 4% at cc. Headwinds in the form of forex and lower sales of acute care products and in-center disposables were partially offset by increase in sales of machines for chronic treatment, peritoneal dialysis and home hemodialysis products.

Geographical Growth

North America

Revenues in the region declined 9% on a year-over-year basis and 1% at cc. On organic basis, sales in the region fell 1%.

EMEA

Revenues in this region decreased 1% on a year-over-year basis, while increasing 1% at cc in the quarter. On organic basis, sales in the region inched up 1%.

Asia-Pacific

Revenues in this region advanced 6% year over year and 10% at cc in the reported quarter. On an organic basis, sales in the region climbed 11%.

Latin America

Revenues in Latin America fell 5% year over year but rose 17% at cc. Organic growth in region was 15%.

2021 Guidance

Fresenius Medical estimates revenues to improve at a low-to-mid-single digit percentage rate. Net income is expected to decline at a high-teens to mid-twenties percentage rate against the 2020 base.

Summing Up

Fresenius Medical exited the first quarter on a mixed note. The company benefited from Health Care Services and Health Care Products units, which witnessed revenue growth in the quarter under review on cc basis. Revenues in the Asia Pacific region witnessed noticeable improvement in the first quarter.

However, Fresenius Medical witnessed decline in revenues in the North America, EMEA and Latin America regions. Further, the company faces intense competition in the field of health care services, and sale of dialysis products, which remains a concern.

Zacks Rank

The company has a Zacks Rank #3 (Hold).

Earnings of Other MedTech Majors at a Glance

Some better-ranked stocks in the broader medical space that have already announced their quarterly results are Integer Holdings Corporation ITGR, Boston Scientific Corporation BSX and HCA Healthcare, Inc. HCA, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Integer Holdings reported first-quarter 2021 adjusted EPS of 97 cents, which surpassed the Zacks Consensus Estimate by 12.8%. First-quarter revenues of $290.5 million outpaced the Zacks Consensus Estimate by 2.6%.

Boston Scientific reported first-quarter 2020 adjusted EPS of 37 cents, which beat the Zacks Consensus Estimate by 32.1%. First-quarter revenues of $2.75 billion outpaced the consensus mark by 5.3%.

HCA Healthcare reported first-quarter 2021 adjusted EPS of $4.14, surpassing the Zacks Consensus Estimate by 23.6%. Net revenues of $14 billion exceeded the Zacks Consensus Estimate by 2.2%.

Zacks Top 10 Stocks for 2021

In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?

Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2021 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report

Integer Holdings Corporation (ITGR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting